Clinical trials of CAR-Ts for MM with published results
| Target . | Institution . | CAR construct . | Conditioning chemotherapy . | Response . | Reference . |
|---|---|---|---|---|---|
| CD138 | Chinese People's Liberation Army General Hospital | Lentivirus; CD28 costimulatory molecule; murine scFv | Varied, all patients received some type of chemotherapy shortly before cell infusion | 5 patients treated; best responses: 4 SD, 1 PD | 36 |
| CD19 | University of Pennsylvania | Lentivirus 4-1BB costimulatory molecule; murine scFv | Melphalan 140-200 mg/m2 prior to ASCT | 10 patients treated; median PFS 185 d (range, 42-479 d) | 10, 35 |
| Immunoglobulin κ light chain | Baylor College of Medicine | γ- retrovirus; CD28 costimulatory molecule; murine scFv | Salvage chemotherapy by referring physician (3 patients) or 12.5 mg/kg cyclophosphamide 4 days prior to CAR-T infusion (4 patients) | 7 patients treated: 4 SD, 3 no response | 21 |
| BCMA | National Cancer Institute | γ-retrovirus; CD28 costimulatory molecule; murine scFv | 3 doses of 300 mg/m2 cyclophosphamide and 3 doses of 30 mg/m2 fludarabine | 12 patients treated; best responses: 1 sCR; 2 VGPR; 1 PR; 8 SD | 9 |
| BCMA | Multicenter; Bluebird Bio | Lentivirus; 4-1BB costimulatory molecule; murine scFv | 3 doses of 300 mg/m2 cyclophosphamide and 3 doses of 30 mg/m2 fludarabine | Among 18 patients with at least 2 mo follow-up, currently, best responses are 4 CR, 7 VGPR, 5 PR, 2 SD | 102 |
| BCMA | University of Pennsylvania | Lentivirus; 4-1BB costimulatory molecule; human scFv | None | 6 patients treated; 1 sCR; 1 VGPR; 4 with minimal or no response | 37 |
| BCMA | The Second Affiliated Hospital of Xi’an Jiaotong University | Not published | Not published | Among 19 patients there was a 100% response rate with 18 patients obtaining sCR or VGPR | 103 |
| Target . | Institution . | CAR construct . | Conditioning chemotherapy . | Response . | Reference . |
|---|---|---|---|---|---|
| CD138 | Chinese People's Liberation Army General Hospital | Lentivirus; CD28 costimulatory molecule; murine scFv | Varied, all patients received some type of chemotherapy shortly before cell infusion | 5 patients treated; best responses: 4 SD, 1 PD | 36 |
| CD19 | University of Pennsylvania | Lentivirus 4-1BB costimulatory molecule; murine scFv | Melphalan 140-200 mg/m2 prior to ASCT | 10 patients treated; median PFS 185 d (range, 42-479 d) | 10, 35 |
| Immunoglobulin κ light chain | Baylor College of Medicine | γ- retrovirus; CD28 costimulatory molecule; murine scFv | Salvage chemotherapy by referring physician (3 patients) or 12.5 mg/kg cyclophosphamide 4 days prior to CAR-T infusion (4 patients) | 7 patients treated: 4 SD, 3 no response | 21 |
| BCMA | National Cancer Institute | γ-retrovirus; CD28 costimulatory molecule; murine scFv | 3 doses of 300 mg/m2 cyclophosphamide and 3 doses of 30 mg/m2 fludarabine | 12 patients treated; best responses: 1 sCR; 2 VGPR; 1 PR; 8 SD | 9 |
| BCMA | Multicenter; Bluebird Bio | Lentivirus; 4-1BB costimulatory molecule; murine scFv | 3 doses of 300 mg/m2 cyclophosphamide and 3 doses of 30 mg/m2 fludarabine | Among 18 patients with at least 2 mo follow-up, currently, best responses are 4 CR, 7 VGPR, 5 PR, 2 SD | 102 |
| BCMA | University of Pennsylvania | Lentivirus; 4-1BB costimulatory molecule; human scFv | None | 6 patients treated; 1 sCR; 1 VGPR; 4 with minimal or no response | 37 |
| BCMA | The Second Affiliated Hospital of Xi’an Jiaotong University | Not published | Not published | Among 19 patients there was a 100% response rate with 18 patients obtaining sCR or VGPR | 103 |